COMP <GO>
IRLA vs AGMB // ALTMAN Z-SCORE & DEBT/EQUITY
IRulya Therapeutics Inc. (NASDAQ) VS. AgomAb Therapeutics NV (NASDAQ) • 15-METRIC TALLY: IRLA 1
— AGMB 1
■ METRIC PARITY
LAST: $33.55 (+1.82%) • MKT CAP: $357.2M
balance-sheet
—
LAST: $6.72 (-10.28%) • MKT CAP: $368.9M
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRLA VS. AGMB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IRLA | AGMB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.19% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.5 | 32.7 | +19.80 | IRLA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $357.2M | $368.9M | -$11.6M | AGMB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IRLA REV | AGMB REV | IRLA GROSS % | AGMB GROSS % | IRLA FCF | AGMB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $162.6M | — | — | — | -$41.8M | — |
| FY 2024 | $160.4M | — | — | — | -$32.2M | — |
| FY 2023 | $96.9M | — | — | — | -$18.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRLA // BETA —
AGMB // BETA —